Garen Manvelian

Regeneron (United States) — United States

Medicine · Health Sciences

27h-index2.9kcitations109works6.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(66), Pharmaceutical Economics and Policy(31), Health Systems, Economic Evaluations, Quality of Life(26), Anesthesia and Pain Management(19), Pain Management and Opioid Use(18)

Publications109 total

Identification of alkaline phosphatase as a putative biomarker of anti-NGF treatment-associated arthropathies: Machine learning-assisted analyses of clinical trial data
Osteoarthritis and Cartilage Open·2025Open Access
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
New England Journal of Medicine·2025· 9 cited
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial
Journal of the American Heart Association·2025Open Access
A Phase 3 trial of fixed-dose combination of fianlimab + cemiplimab vs relatlimab + nivolumab in patients with unresectable or metastatic melanoma
EJC Skin Cancer·2025Open Access
Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
American Journal of Preventive Cardiology·2024Open Access
Abstract 4140467: The Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results from the ODYSSEY OUTCOMES Trial
Circulation·2024
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome
Journal of the American College of Cardiology·2024· 12 citedOpen Access
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.
Journal of Clinical Oncology·2024· 2 cited
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy·2024· 16 citedOpen Access
Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
JAMA Pediatrics·2024· 25 citedOpen Access
Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis
Critical Care Explorations·2023· 1 citedOpen Access
Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins
European Heart Journal·2023· 1 citedOpen Access
Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
Journal of the American Heart Association·2023· 33 citedOpen Access
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
Cancer Medicine·2023· 8 citedOpen Access
Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes
BMC Ophthalmology·2023Open Access
Effect of alirocumab on cataracts in patients with acute coronary syndromes
BMC Ophthalmology·2023· 4 citedOpen Access
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
European Heart Journal·2023· 43 citedOpen Access
Abstract 10291: Elevated C-Reactive Protein Level Amplifies the Association of Lipoprotein(a) With Cardiovascular Risk and Risk Reduction With Alirocumab After Acute Coronary Syndrome
Circulation·2022
Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
Arteriosclerosis Thrombosis and Vascular Biology·2022· 37 citedOpen Access
Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial
European Heart Journal·2022· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Robert Pordy(17), Gregory G. Schwartz(16), Michael Szarek(16), Philippe Gabríel Steg(14), Shaun G. Goodman(14), Marie T. Baccara‐Dinet(13), J. Wouter Jukema(12), Rafael Díaz(11), Deepak L. Bhatt(11), Harvey D. White(11), Vera Bittner(10), Robert A. Harrington(8), Michel Scemama(7), Gavin Martin(6), Andreas M. Zeiher(6), Kausik K. Ray(6), Michel Farnier(6), Patricio López‐Jaramillo(5), William J. Sasiela(5), Róbert Gábor Kiss(5)